RD06-04 / Nanjing Bioheng Biotech, Wuhan Union Hospital - LARVOL DELTA

Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Nanjing Bioheng Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • ANCA Vasculitis • Immunology • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Nanjing Bioheng Biotech Co., Ltd.

CAR T-Cell Therapy • New P1 trial • ANCA Vasculitis • Immunology • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

Clinical Study on Targeted CD19 CAR-T Therapy for Autoimmune Diseases (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Nanjing Bioheng Biotech Co., Ltd.

New P1 trial • ANCA Vasculitis • Immunology • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

A Study of RD06-04 in Patients With Active Autoimmune Diseases (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Nanjing Bioheng Biotech Co., Ltd.

CAR T-Cell Therapy • New P1 trial • ANCA Vasculitis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Neuromyelitis Optica Spectrum Disorder • Systemic Lupus Erythematosus • Vasculitis

Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus (clinicaltrials.gov) - P=N/A | N=12 | Recruiting | Sponsor: Wuhan Union Hospital, China

CAR T-Cell Therapy • New trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus